Precigen, Inc.

Latest Report Overview

Precigen Inc (PGEN) reported For the quarterly period ended March 31, 2026 (Issuer fiscal Q1 FY2026) revenue of $23.25 million (+1633.9% YoY) with a net loss of $7.93 million (diluted EPS -$0.02) and an 89% gross margin. The quarter reflects significant year-over-year revenue growth due to low prior-year comparables and ongoing investment in clinical programs. Management continues to prioritize the advancement of its primary clinical pipelines, particularly the UltraCAR-T and AdenoVerse platforms. The company maintains a high-burn operational model, with R&D expenditures representing a significant portion of operating outflow. Efforts are focused on achieving pivotal clinical milestones that could validate the therapeutic potential of their platforms and attract further strategic partnership interest. Liquidity remains a central concern, as the company operates with negative operating and free cash flows. Future financial performance will depend heavily on the ability to sustain clinical momentum, control cash burn, and navigate the capital-intensive nature of the biotechnology development cycle without excessive dilution.

Key Takeaways for Precigen Inc

• Precigen reported a significant revenue increase to $23.25 million for Q1 2026, though this growth reflects a very low prior-year base and does not indicate sustained commercial profitability.
• The company continues to burn substantial capital, with $44.08 million in negative free cash flow for Q1 2026, reflecting high R&D and operating costs.
• Clinical pipeline advancement remains the core operational focus, with capital allocation directed almost exclusively toward R&D and development milestones.
• Liquidity remains an existential concern, evidenced by a cash position of $7.48 million against a total debt load of $93.52 million.
• The company's valuation remains speculative, trading at high multiples (EV/Sales ~73x) that rely entirely on the future success of clinical trials rather than current earnings power.
• Strategic reliance on partnerships is key; future sustainability depends on the company's ability to secure or expand collaborations for its gene and cell therapy platforms.

What Does Precigen Inc Do?

Precigen Inc is a biotechnology company that discovers and develops innovative gene and cell therapies to address severe diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Its core business centers on proprietary technology platforms, including the UltraCAR-T platform for CAR-T cell therapy and the AdenoVerse platform for gene delivery, which aim to improve speed, cost, and patient access compared to traditional therapies. The company operates primarily as a clinical-stage developer, working with research collaborators and potential clinical partners to move candidates through the regulatory process. The business model is focused on proving the efficacy of these novel therapeutics to build long-term value, rather than immediate commercial sales. It operates globally, with its research and development facilities forming the primary base of operations.

Growth Drivers for Precigen Inc

• Progression of the UltraCAR-T platform through clinical trial stages.
• Advancement of the AdenoVerse platform for vaccine and therapeutic applications.
• Securing new, high-value strategic partnerships and licensing deals for existing assets.
• Successful completion of clinical milestones triggering contractual payments from partners.
• Expanding the therapeutic scope of current platforms to new disease verticals.